Aplastic anemia is a rare, life-threatening blood disorder where patients are unable to make enough blood cells due to the ...
Researchers at Dresden University Hospital may have discovered a new therapeutic approach for treating myelodysplastic ...
We studied bone marrow (BM) histologic abnormalities in myelodysplastic syndromes (MDS) classified according to WHO criteria to determine their clinical correlates and prognostic value. From the ...
Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
Myelodysplastic syndromes (MDS) are blood cancers where bone marrow makes atypical red cells, white cells, or platelets. These cells may die early or not work well. Less aggressive MDS may still allow ...
Purpose: The most recent and powerful prognostic instrument established for myelodysplastic syndromes (MDS) is the International Prognostic Scoring System (IPSS), which is primarily based on medullary ...
The rare disease Fanconi anemia is an inherited bone marrow disorder linked to birth defects that leads to failure of bone marrow, the spongy material inside the bones where stem cells develop.
MPNs involve overproduction of blood cells, while MDS results in poorly formed cells, affecting blood cell function and counts. Diagnosis requires blood tests, bone marrow biopsy, and genetic testing ...
Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results